594

Synthetic, Non-natural Ceramide Analogs as Apoptotic Agents in Prostate Cancer

Dagan Arie, HUJI, School of Medicine - IMRIC

Results in mouse and human cell models validate approach

Categories

Ceramide, apoptosis, cancer, sphingolipids, prostate cancer

Development Stage

Considerable anticancer activity in vivo in prostate, colon, pancreas and melanoma mouse models of human tumors. In vitro activity in various human cancer cell lines.

Patent Status

Filed in US, Europe, Japan and Israel

Second provisional patent filed

Market Size

$8B

 

Highlights

  • Novel new compounds
  • Considerable anticancer activity observed with local or even in metastatic cancer of prostate, colon, pancreas and melanoma mice models. Analog were injected intradermally or intraperitoneally or given per os to mice bearing human tumors.
  • Provides powerful stand alone or adjunctive therapy with irradiation or chemotherapy for cancer
  • Elevates cellular ceramide, inducing cytotoxicity and death by apoptosis
  • Leverages proven treatment models

 

Our Innovation

  • Synthetic compounds activates procaspase-3 and induce apoptosis
  • Increase the caspase-3 activity six to seven fold
  • Treatment with an analog resulted in tumor regression in mice

 

The Opportunity

  • Provides more efficacious cancer treatment
  • Attenuates treatment process, reducing patient discomfort
  • Addresses needs for expanding cancer market

 

Development Milestones

  • Further in vivo mouse models
  • Pharmacokinetic pharmacodynamic experiments
  • In vivo human testing

Patent Status

Granted US 8,962,891; US 9,340,488; Europe 2217560

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608
Contact ME:
Image CAPTCHA